Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
07:00am, Thursday, 15'th Feb 2024
Revenue from Blueprint's rare-disease drug topped fourth-quarter expectations, but BPMC stock could topple on its light outlook for the year.
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
07:00am, Thursday, 15'th Feb 2024
-- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of app
Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:22am, Monday, 12'th Feb 2024
Besides Wall Street's top -and-bottom-line estimates for Blueprint Medicines (BPMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared d
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Thursday, 08'th Feb 2024
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
01:35pm, Tuesday, 16'th Jan 2024
Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
What Makes Blueprint Medicines (BPMC) a New Buy Stock
01:33pm, Tuesday, 16'th Jan 2024
Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
02:17pm, Wednesday, 13'th Dec 2023
Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
08:23am, Monday, 11'th Dec 2023
Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine po
Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat
09:02am, Friday, 27'th Oct 2023
Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.
Why Blueprint Medicines Stock Soared Today
05:47pm, Thursday, 26'th Oct 2023
Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patients were using the ISM treatment at the end of Q3.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
09:48am, Thursday, 26'th Oct 2023
Blueprint Medicines (BPMC) came out with a quarterly loss of $2.20 per share versus the Zacks Consensus Estimate of a loss of $2.39. This compares to loss of $2.23 per share a year ago.
Earnings Preview: Blueprint Medicines (BPMC) Q3 Earnings Expected to Decline
11:19am, Thursday, 19'th Oct 2023
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines: At The Forefront Of Groundbreaking Cancer Treatments
11:40am, Thursday, 03'rd Aug 2023
On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicin
Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates
02:12pm, Wednesday, 02'nd Aug 2023
Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.
